Skip to main content

Table 3 Unadjusted and adjusted costs, SF6D utility scores and QALYs among DESIR patients satisfying selected criteria sets

From: Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates

  Canada n = 169 France n = 197 UK n = 86 Germany n = 175 Hong Kong n = 61
Anti-TNF non-user (n = 98) Anti-TNF user (n = 71) Anti-TNF non-user (n = 117) Anti-TNF user (n = 80) Anti-TNF non-user (n = 46) Anti-TNF user (n = 40) Anti-TNF non-user (n = 108) Anti-TNF user (n = 67) Anti-TNF non-user (n = 29) Anti-TNF user (n = 32)
Unadjusted 
 Total costs (Mean ± SD) 1981 ± 2812 15,448 ± 6155 2117 ± 2976 15,311 ± 5801 1426 ± 1852 16,475 ± 7506 2044 ± 3351 15,339 ± 6453 1697 ± 2447 15,132 ± 6548
 Health Practitioner 655 ± 745 896 ± 772 640 ± 720 1000 ± 939 440 ± 573 971 ± 1034 605 ± 750 953 ± 1013 472 ± 722 835 ± 682
 Hospital 532 ± 1289 710 ± 2010 615 ± 1505 678 ± 1913 530 ± 1326 646 ± 1394 454 ± 1090 731 ± 2036 695 ± 1541 591 ± 1184
 Medical Act 178 ± 238 399 ± 362 185 ± 247 396 ± 352 155 ± 239 449 ± 417 154 ± 228 386 ± 313 162 ± 330 433 ± 388
 Medication 149 ± 135 12,511 ± 5252 143 ± 132 12,364 ± 5114 126 ± 100 12,742 ± 5844 145 ± 125 12,409 ± 5497 138 ± 120 11,981 ± 4977
 Productivity 467 ± 1893 932 ± 2796 534 ± 1987 872 ± 2411 176 ± 526 1667 ± 4059 687 ± 2661 859 ± 2776 231 ± 672 1292 ± 3271
 Total costs: Med (IQR) 913 (362, 2343) 14,172 (12,741, 17,495) 920 (364, 2343) 14,293 (12,806, 17,537) 839 (326, 1621) 14,963 (13,110, 18,742) 865 (323, 2092) 14,111 (12,825, 16,356) 809 (298, 1681) 14,404 (12,579, 17,222)
SF6D (Mean ± SD)
 Index 0.579 ± 0.101 0.532 ± 0.078 0.579 ± 0.098 0.533 ± 0.075 0.602 ± 0.088 0.528 ± 0.074 0.594 ± 0.105 0.536 ± 0.079 0.594 ± 0.078 0.531 ± 0.073
 6 M after index visit 0.645 ± 0.108 0.644 ± 0.130 0.638 ± 0.105 0.635 ± 0.128 0.644 ± 0.103 0.630 ± 0.130 0.650 ± 0.111 0.652 ± 0.132 0.609 ± 0.094 0.624 ± 0.128
 12 M after INDEX VISit 0.647 ± 0.118 0.620 ± 0.123 0.639 ± 0.115 0.612 ± 0.122 0.639 ± 0.108 0.609 ± 0.112 0.646 ± 0.124 0.632 ± 0.123 0.633 ± 0.099 0.595 ± 0.107
 Total QALY (Mean ± SD) 0.63 ± 0.09 0.61 ± 0.10 0.62 ± 0.09 0.60 ± 0.10 0.63 ± 0.08 0.60 ± 0.10 0.63 ± 0.09 0.62 ± 0.10 0.61 ± 0.07 0.59 ± 0.09
Adjusted (Mean ± SE)
 Total costs 1703 ± 366 15,741 ± 802 1763 ± 347 15,773 ± 687 756 ± 644 16,952 ± 1160 1874 ± 408 15,617 ± 852 722 ± 946 15,764 ± 1229
 Total QALY 0.61 ± 0.01 0.63 ± 0.01 0.61 ± 0.01 0.62 ± 0.01 0.61 ± 0.01 0.63 ± 0.02 0.62 ± 0.01 0.64 ± 0.01 0.59 ± 0.02 0.62 ± 0.02